Nomura Holdings’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nomura Holdings’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.13M	Sell	15,500 -2,500	-14%	-$851K	0.01%	630
2025 Q4	$7.16M	Sell	18,000 -9,000	-33%	-$3.98M	0.01%	657
2025 Q3	$12.3M	Buy	+27,000	New	+$11M	0.02%	462
2024 Q4	–	Sell	-1,500	Closed	-$413K	–	2158
2024 Q3	$413K	Sell	1,500 -9,800	-87%	-$2.55M	﹤0.01%	1292
2024 Q2	$2.75M	Buy	+11,300	New	+$1.78M	0.01%	849

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings's ALNY Position: Q1 2026 in Review

Nomura Holdings reduced its Alnylam Pharmaceuticals (ALNY) stake by 36% in Q1 2026, selling an estimated $2.77M and leaving 14,299 shares worth $4.73M. The position accounts for 0.01% of the portfolio, ranked #664.

Nomura Holdings first reported a position in ALNY in Q3 2013 and has held it in 22 quarters since. The position peaked at $9.05M in Q2 2015. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Nomura Holdings held 14,299 shares of Alnylam Pharmaceuticals worth $4.73M as of Q1 2026.
Nomura Holdings sold 8,138 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.77M.
Alnylam Pharmaceuticals made up 0.01% of Nomura Holdings's portfolio in Q1 2026, its #664 holding.
Nomura Holdings first reported a position in Alnylam Pharmaceuticals in Q3 2013 and has held it in 22 quarters since.
Nomura Holdings's Alnylam Pharmaceuticals position peaked at $9.05M in Q2 2015.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.